The Medicines and Healthcare products Regulatory Agency (MHRA) has today authorised this new indication for Anastrozole, a hormone treatment used for breast cancer in post-menopausal women.
Anastrozole was already authorised for use in the treatment of breast cancer in post-menopausal women and has been used off-label for prevention.
Today’s announcement confirms the authorisation for prevention in post-menopausal women at moderate or high risk of developing the disease.
Evidence was based on the IBIS-II study, an international, randomised double-blind, placebo-controlled trial, which showed fewer women developed breast cancer in the anastrozole group compared to the placebo group…
